Yun Wu, Chen Cui, Fang-Fang Bi, Cheng-Yu Wu, Jin-Rui Li, Yu-Meng Hou, Ze-Hong Jing, Qing-Ming Pan, Miao Cao, Li-Fang Lv, Xue-Lian Li, Hong-Li Shan, Xin Zhai, Yu-Hong Zhou
Montelukast, cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, is used clinically for patients with asthma, chronic obstructive pulmonary diseases (COPD), and allergic rhinitis. It has been reported that CysLT1R antagonists could reduce the risks of cardiovascular diseases in animal studies. Cardiac fibrosis is one of the major causes of heart failure. But little is known about the role of Montelukast in cardiac fibrosis and its underlying mechanism. In transverse aortic constriction (TAC) mice, Montelukast improved cardiac pumping function and inhibited cardiac fibrosis by down-regulation of the proteins related to the fibrosis, such as connective tissue growth factor (CTGF), Transforming Growth Factor β (TGF-β), and Alpha-smooth muscle actin (α-SMA)...
May 15, 2022: European Journal of Pharmacology